Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...
Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback